Clinical Trials Logo

Stable Angina clinical trials

View clinical trials related to Stable Angina.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01918150 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII

EVIDENCE II
Start date: March 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effectiveness and safety, at 24 months, of the TITAN2 stent to any bare-metal stent (BMS) in Cobalt-Chromium in a population presenting an indication for these stents among 40% of which present an acute coronary syndrome (ACS).

NCT ID: NCT01687686 Active, not recruiting - Stable Angina Clinical Trials

Differential Effects of Lipids on Cardiovascular Diseases: A CALIBER Study

Start date: January 2001
Phase: N/A
Study type: Observational

The role of lipids as risk factors for cardiovascular events is well-documented, although events studied have largely been broad classes without specific detail. This study will examine a more refined set of endpoints.

NCT ID: NCT01623180 Active, not recruiting - Bleeding Clinical Trials

A Randomized Clinical Evaluation of the BioFreedomâ„¢ Stent

Leaders Free
Start date: December 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate that a BioFreedomâ„¢ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and definite/probable stent thrombosis, and that its efficacy is superior to a bare metal stent as measured by clinically driven TLR at one year.

NCT ID: NCT00185263 Active, not recruiting - Stable Angina Clinical Trials

Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina

AGENT-4
Start date: March 2002
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality of life, and cardiovascular outcomes. To doses are to be studied, 2.87x10(8) and 2.87x10(9) viral particles, to evaluate the dose-response of Ad5FGF-4. Short-term and long-term safety of Ad5FGF-4 will also be evaluated.